Scarica l'app Stockscreener
2.37
14.49%
0.30
Pre-mercato:
2.37
Precedente Chiudi:
$2.07
Aprire:
$2.11
Volume 24 ore:
5.61M
Relative Volume:
2.44
Capitalizzazione di mercato:
$517.09M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-8.4643
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
+25.40%
1M Prestazione:
+29.51%
6M Prestazione:
+75.56%
1 anno Prestazione:
+69.29%
Intervallo 1D:
$2.07
$2.37
Intervallo di 1 settimana:
$1.90
$2.37
Portata 52W:
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Confronta AKBA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.37 | 517.09M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 10.9%Should You Buy? - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Bought by Barclays PLC - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
Equities Analysts Issue Forecasts for AKBA FY2024 Earnings - Defense World
What is HC Wainwright's Forecast for AKBA FY2024 Earnings? - MarketBeat
Brokers Set Expectations for AKBA FY2024 Earnings - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Increase in Short Interest - MarketBeat
Analysts Offer Predictions for AKBA FY2029 Earnings - MarketBeat
Brokers Issue Forecasts for AKBA FY2029 Earnings - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from HC Wainwright - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Rating Lowered to Sell at StockNews.com - MarketBeat
H.C. Wainwright optimistic on Akebia shares despite risks to commercial opportunity - Investing.com Nigeria
HC Wainwright Reiterates "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Akebia announces ‘multiple positive business updates’ - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Jane Street Group LLC - Defense World
Vafseo tablets start U.S. shipment, Akebia plans Phase 3 trial - Investing.com India
Akebia Therapeutics Announces Multiple Positive Business Updates - citybiz
Akebia's Vafseo Launch Secures Coverage for Nearly All U.S. Dialysis Patients, 99% of Doctors Show Interest - StockTitan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald
Akebia Therapeutics (NASDAQ:AKBA) Upgraded at StockNews.com - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Holdings Lifted by Barclays PLC - Defense World
Geode Capital Management LLC Has $6.28 Million Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
New Strong Sell Stocks for January 3rd - Yahoo Finance
Akebia Therapeutics Awards Inducement Stock Options to New Employee at $1.90 Per Share - StockTitan
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Expands By 21.7% - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - MarketBeat
State Street Corp Purchases 683,287 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Purchased by State Street Corp - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com
Wellington Management Group LLP Takes $534,000 Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years - Yahoo Finance
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - The Eastern Progress Online
Akebia Therapeutics CEO to Present Vafseo Launch Updates at J.P. Morgan Healthcare Conference 2024 - StockTitan
Cyclerion Strikes $560M Milestone Deal with Akebia, Completes Portfolio Monetization Strategy - StockTitan
Akebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Hold Rating - MarketBeat
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - Kilgore News Herald
Akebia Therapeutics to Present at Upcoming Investor Conferences - The Eastern Progress Online
New Strong Sell Stocks for December 5th - Yahoo Finance
Akebia Therapeutics (FRA:AX9) EBITDA : €4.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):